Publications by authors named "Reliquet V"
Article Synopsis
- The SMILE trial investigated the effectiveness and safety of switching children living with HIV to a treatment regimen of integrase inhibitor (INSTI) and boosted darunavir (DRV/r), compared to continuing standard triple antiretroviral therapy (SOC).
- The trial enrolled 318 participants aged 6-18 from multiple regions, finding that switching to the new regimen showed non-inferiority in maintaining low HIV-RNA levels after 48 weeks.
- The results indicated no significant differences in safety between the two groups, but the INSTI + DRV/r group had greater increases in weight and BMI compared to those on SOC.
Article Synopsis
- The study aims to assess the prevalence of measles antibodies among adults living with HIV in France, focusing on those born after the measles vaccine was introduced.
- Conducted between April 2019 and April 2020, it involved 648 participants, finding that 87.2% had positive measles serology, but only 81.8% of vaccinated individuals tested positive.
- Key factors associated with a lack of measles antibodies included younger age, being born in France, and having fewer social vulnerabilities, highlighting the need for better vaccination tracking in this population.
Article Synopsis
- The study aimed to investigate if using integrase strand transfer inhibitors (INSTIs) like raltegravir at conception is linked to birth defects or adverse pregnancy outcomes, in light of past concerns about dolutegravir.
- Researchers analyzed data from a national French Perinatal Cohort, comparing women exposed to INSTIs during pregnancy with those taking darunavir/ritonavir, matching them on various factors like age and delivery year.
- Results showed a slightly higher birth defect rate (6.7%) in infants exposed to raltegravir at conception, but not significantly different when compared to matched controls; no other significant pregnancy outcomes were found, highlighting the need for further research with larger data sets.
Introduction: The metabolic pathways of dolutegravir suggest a potential predator effect of nevirapine on dolutegravir pharmacokinetics and switching from a nevirapine- to a dolutegravir-containing regimen could lead to a lower and suboptimal exposure to dolutegravir several weeks after the switch in case of persistent inducer effect.
Patients And Method: Prospective, pilot, single-arm, open-label, non-comparative, bicentric study to evaluate the pharmacokinetics, virologic outcomes, safety, and patient satisfaction of switching from abacavir/lamivudine and nevirapine to a single tablet of abacavir/lamivudine/dolutegravir. The primary endpoint was the maintenance of virologic suppression (HIV-1 RNA<50 copies/mL) at week 12.
Article Synopsis
- The study aimed to investigate metabolic risk factors in young adults who have lived with HIV since childhood, comparing their profiles to a control group from the general population.
- It involved analyzing data from 268 HIV-infected patients and 245 individuals from a national survey, measuring various health metrics like BMI, blood pressure, and cholesterol levels.
- Results showed that HIV-infected young adults had higher rates of metabolic abnormalities, particularly dyslipidemia and unhealthy fat distribution, indicating a need for careful monitoring of their cardiovascular health.
Article Synopsis
- - Severe combined immunodeficiency (SCID) screening at birth uses T-receptor excision circles to assess newborn immunity and understand maternal health impacts.
- - A study in France showed a small drop in immunity among newborns of HIV-infected mothers.
- - This decrease in immune response is influenced by factors such as prematurity and the infants' African ethnicity.
Article Synopsis
- - Antiretroviral therapy (ART) for HIV-positive pregnant women has reduced mother-to-child transmission rates, but there are concerns about potential negative effects on children's development due to ART exposure.
- - A study conducted on women who delivered at Nantes hospital found a 33% response rate, revealing that over 10 years, some children experienced behavioral disorders, cognitive delays, and even cases of cancer.
- - The research suggests a significant link between neurodevelopmental disorders, preterm birth, and exposure to certain antiretroviral drugs (3 NRTIs), highlighting the need for more extensive studies and lifelong follow-up of affected children.
Objectives: Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are limited.
Methods: We analysed four polymorphisms in the CYP2B6 (516 G>T), CYP3A5 (6986 A>G) and ATP-binding cassette, sub-family B, member 1 (ABCB1) (2677 G>T/A and 3435 C>T) genes in HIV-infected adults virologically suppressed on a protease inhibitor-based regimen who switched to a regimen containing emtricitabine, didanosine and efavirenz in the setting of the ANRS ALIZE trial.
Article Synopsis
- The study assesses the long-term effects of nucleos(t)ide reverse transcriptase inhibitors (NRTIs), particularly didanosine, on cancer risk in children born to HIV+ mothers, suggesting a need for further evaluation of antiretroviral exposure during pregnancy.
- Out of 15,163 children analyzed, 21 cancers were identified, with didanosine linked to one-third of cases, despite it being a minor part of overall prescriptions.
- The findings indicate that first-trimester exposure to didanosine significantly increases cancer risk, highlighting its potential oncogenic effects and the importance of assessing genotoxicity for this class of drugs.
Article Synopsis
- The study aimed to assess how nevirapine affects the pharmacokinetics of dolutegravir in HIV-1 patients, due to a potential interaction between the two drugs.
- Ten patients received dolutegravir alongside nevirapine and were monitored for changes in drug levels over a 5-day period, with follow-up assessments.
- Results showed that nevirapine significantly reduced dolutegravir levels, indicating that patients might require higher dolutegravir doses to achieve effective treatment.
This cross-sectional study evaluates the prevalence and factors associated with sleep disturbances in French adult HIV-infected outpatients. Patients fullfilled a self-administered questionnaire on their health behavior, sleep attitudes (Pittsburgh sleep quality index, PSQI), quality of life and depression; 1354 patients were enrolled. Median sleeping time was 7 h.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the role of highly active antiretroviral therapy (ART) in preventing perinatal transmission (PT) of HIV-1, focusing on when treatment is initiated relative to conception.
- An analysis of 8,075 mother-infant pairs from a French cohort found that 0.7% experienced PT, with zero transmissions among those who began ART before conception and maintained a low viral load (VL).
- Results show that starting ART earlier significantly lowers PT rates, highlighting the importance of VL control before and during pregnancy in HIV-infected women.
Article Synopsis
- The case highlights a rare instance of mother-to-child transmission (MTCT) of HIV, occurring despite the mother having a suppressed viral load at delivery, which is significant considering the overall low MTCT rates due to antiretroviral therapy advancements in France.* -
- The mother, diagnosed with HIV-1, had inconsistent adherence to her antiretroviral therapy during pregnancy, leading to a viral rebound that complicated her treatment and ultimately resulted in in-utero transmission of the virus to her infant.* -
- Following the infant’s diagnosis with HIV, standard treatment protocols were initiated, emphasizing the need for consistent maternal adherence to therapy to prevent transmission and ensure better health outcomes for infants born to HIV-positive mothers.*
Article Synopsis
- Sleep disturbances are common in HIV-infected patients, with 47% reporting issues, especially among women and those experiencing depression.
- A study in France assessed 1,354 HIV patients using questionnaires to gather data on sleep quality, quality of life, and depression.
- Key factors linked to sleep disturbances included depression, being single, and smoking, while active employment and male gender seemed to reduce risk.
Objectives: Nevirapine is an inducer of hepatic metabolism. After discontinuation, nevirapine has an inductive effect on cytochrome P450 3A4, which persists for a few weeks and which, after switching to rilpivirine, may reduce rilpivirine exposures and have a negative clinical impact. This study evaluates the virological outcome, pharmacokinetics and safety of switching virologically suppressed, HIV-1-infected patients from nevirapine to rilpivirine.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 39 patients analyzed, a high percentage maintained undetectable HIV levels (below 50 copies/ml) for up to 36 months after switching, with no significant adverse effects reported.
- * The findings suggest that NVP-RAL combination therapy is a viable option for patients who cannot tolerate traditional NRTI or PI/ritonavir treatments, warranting further research.
Article Synopsis
- Long-term antiretroviral therapy for HIV-1 aims to suppress viral load and reduce immune activation, particularly through using NNRTI-containing regimens.
- A study evaluated the effects of long-term treatment with nevirapine or efavirenz on residual viremia and monocyte activation in patients with controlled viral loads (<50 copies/ml).
- Results showed that 75% of the 421 participants had residual viremia <1 copy/ml, with the duration of low viral load being the key factor, and nevirapine was linked to lower monocyte activation compared to efavirenz.
Objectives: Tenofovir may be associated with nephrotoxicity. Several studies have shown that an early increase in urinary neutrophil gelatinase-associated lipocalin (NGAL) may predict the occurrence of acute kidney injury. We investigated urine and plasma NGAL in patients on long-term treatment with nevirapine associated with either tenofovir/emtricitabine or abacavir/lamivudine.
View Article and Find Full Text PDFObjective: The authors had for aim to describe the effectiveness and the safety of a saquinavir/ritonavir (SQV/r) regimen, 1000/100mg twice daily, in HIV-infected pregnant patients.
Patients And Method: We made a prospective and observational study of HIV positive female patients beginning or going on SQV/r antiretroviral treatment (ART) during pregnancy.
Results: Sixty-two patients were enrolled from July 2007 to June 2009 in 10 infectious diseases units in France.
Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
Fundam Clin Pharmacol
August 2012
Article Synopsis
- The study examined how darunavir resistance mutations and its plasma concentration relate to the virological response in HIV-infected patients with prior treatment experience.
- Using a retrospective analysis of 48 patients, researchers applied multivariate logistic regression to explore these relationships.
- The findings indicated that the count of specific darunavir resistance mutations, adjusted for mutations with positive effects, was the only statistically significant predictor of virological response, highlighting the importance of considering both negative and positive mutation impacts.
Article Synopsis
- A clinical trial (ALIZE ANRS 099) studied the long-term effects of a once-daily HIV treatment combining efavirenz, emtricitabine, and didanosine in 355 adults switching from a protease inhibitor regimen.
- After 42 months, 68% of patients remained on the efavirenz regimen, showing significant viral suppression (62% had HIV RNA levels <400 copies/mL).
- The treatment was well tolerated, with few reported side effects, no cases of lipodystrophy, and improvements in CD4 counts and lipid profiles over the four years.
Objective: To describe safety and long-term efficacy of nevirapine (NVP) in a real-life setting.
Results: From 1996 to 2008, among the 745 patients who received NVP, 592 were still followed in our center; of these, 231 had stopped NVP because of failure (42%), side effects (28%), other causes (30%). Twenty-seven percent of discontinuations occurred in the first 3 months; 68% were related to adverse events.